Journal
ARCHIVES OF VIROLOGY
Volume 155, Issue 11, Pages 1765-1775Publisher
SPRINGER WIEN
DOI: 10.1007/s00705-010-0756-3
Keywords
-
Categories
Funding
- National 973 Project [2010CB530301]
- National Natural Science Foundation of China [30972623]
- National Key Technology R&D Program of China [2006BAD06A03]
- Science and Technology Commission of Shanghai Municipality [09DZ1908600, 10XD1422200]
- Chinese Academy of Sciences [KSCXI-YW-R-14]
Ask authors/readers for more resources
Vaccination is a cost-effective way to control the influenza epidemic. Vaccines based on highly conserved antigens can provide protection against different influenza A strains and subtypes. In this study, the recombinant nucleoprotein (rNP) of the A/PR/8/34 (H1N1) influenza virus strain was effectively expressed using a prokaryotic expression system and then purified with a nickel-charged Sepharose affinity column as a candidate component for an influenza vaccine. The rNP was administered intranasally three times at 3-week intervals to female BALB/c mice in combination with an adjuvant (cholera toxin B subunit containing 0.2% of the whole toxin). Twenty-one days after the last immunization, the mice were challenged with homologous or heterologous influenza viruses at a lethal dose. The results showed that intranasal immunization of 10 mu g rNP with adjuvant completely protected the immunized mice against the homologous influenza virus, and immunization with 100 mu g rNP in combination with adjuvant provided good cross-protection against heterologous H5N1 and H9N2 avian influenza viruses. The results indicate that such a vaccine administered intranasally can induce mucosal and cell-mediated immunity, thus having the potential to control epidemics caused by new emerging influenza viruses.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available